Evidence map›Paper›PMID 33037320›Full record

Trial reportCommunications biology2020

Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.

Virginie Rozot, Elisa Nemes, Hennie Geldenhuys, Munyaradzi Musvosvi, Asma Toefy, Frances Rantangee, Lebohang Makhethe, Mzwandile Erasmus, Nicole Bilek, Simbarashe Mabwe and 11 more

Open access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Role of MHC class I pathways inFrontiers in cellular and infection microbiology · 2023
    Review
  7. Article
  8. Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 4 countries.

Virginie Rozot *South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. virginie.rozot@uct.ac.za.ORCID http://orcid.org/0000-0001-9757-1501
Elisa Nemes *South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-1662-4961
Hennie GeldenhuysSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Munyaradzi MusvosviSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Asma ToefySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Frances RantangeeSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Lebohang MakhetheSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Mzwandile ErasmusSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Nicole BilekSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Simbarashe MabweSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Greg FinakFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4341-9090
William FulpFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
Ann M GinsbergAERAS, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-4299-2031
David A HokeyAERAS, Rockville, MD, USA.
Muki SheyAeras South Africa Endpoint Assay Laboratory, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-8776-4737
Sanjay GurunathanSanofi Pasteur, Swiftwater, PA, USA.
Carlos DiazGranadosSanofi Pasteur, Swiftwater, PA, USA.
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. thomas.scriba@uct.ac.za.ORCID http://orcid.org/0000-0002-0641-1359
C-040-404 Study Team
University of Cape Town · ZAAeras · USDesmond Tutu HIV Foundation · ZASanofi (United States) · USFred Hutch Cancer Center · USStatens Serum Institut · DKSanofi (Canada) · CA

Funding

Wellcome Trust 211360/Z/18/Z
6 · The paper itself

Abstract

We characterize the breadth, function and phenotype of innate and adaptive cellular responses in a prevention of Mycobacterium tuberculosis infection trial. Responses are measured by whole blood intracellular cytokine staining at baseline and 70 days after vaccination with H4:IC31 (subunit vaccine containing Ag85B and TB10.4), Bacille Calmette-Guerin (BCG, a live attenuated vaccine) or placebo (n = ~30 per group). H4:IC31 vaccination induces Ag85B and TB10.4-specific CD4 T cells, and an unexpected NKT

Indexed as

Adaptive ImmunityAdolescentBCG VaccineCD4-Positive T-LymphocytesChildCytokinesHumansImmunity, InnateInterferon-gammaMycobacterium tuberculosisNatural Killer T-CellsTh1 CellsTuberculosis, PulmonaryTuberculosis VaccinesBCG VaccineCytokinesInterferon-gammaTuberculosis Vaccines

Identifiers

PMID33037320
PMCPMC7547090
OpenAlexW3092241409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.